[go: up one dir, main page]

CL2007001590A1 - Compuestos derivados de tioxantina; inhibidores de la enzima mieloperoxidasa (mpo); composicion farmaceutica; y su uso para tratar desordenes inflamatorios como esclerosis multiple, mal de parkinson, ateroesclerosis, enfermedad pulmonar obstructiva cronica (copd), bronquitis infecciosa y eosinofilica y fibrosis quistica. - Google Patents

Compuestos derivados de tioxantina; inhibidores de la enzima mieloperoxidasa (mpo); composicion farmaceutica; y su uso para tratar desordenes inflamatorios como esclerosis multiple, mal de parkinson, ateroesclerosis, enfermedad pulmonar obstructiva cronica (copd), bronquitis infecciosa y eosinofilica y fibrosis quistica.

Info

Publication number
CL2007001590A1
CL2007001590A1 CL2007001590A CL2007001590A CL2007001590A1 CL 2007001590 A1 CL2007001590 A1 CL 2007001590A1 CL 2007001590 A CL2007001590 A CL 2007001590A CL 2007001590 A CL2007001590 A CL 2007001590A CL 2007001590 A1 CL2007001590 A1 CL 2007001590A1
Authority
CL
Chile
Prior art keywords
disease
parkinson
pharmaceutical composition
mpo
copd
Prior art date
Application number
CL2007001590A
Other languages
English (en)
Inventor
Inc Genentech
Biopharma Inc Array
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2007001590A1 publication Critical patent/CL2007001590A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos derivados de tioxantina; composición farmacéutica; y uso en el tratamiento de desórdenes inflamatorios, neuroinflamatorios, tales como Parkinson, esclerosis múltiple, bronquitis, epoc, entre otras.
CL2007001590A 2006-06-05 2007-06-01 Compuestos derivados de tioxantina; inhibidores de la enzima mieloperoxidasa (mpo); composicion farmaceutica; y su uso para tratar desordenes inflamatorios como esclerosis multiple, mal de parkinson, ateroesclerosis, enfermedad pulmonar obstructiva cronica (copd), bronquitis infecciosa y eosinofilica y fibrosis quistica. CL2007001590A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81091906P 2006-06-05 2006-06-05

Publications (1)

Publication Number Publication Date
CL2007001590A1 true CL2007001590A1 (es) 2008-01-25

Family

ID=38801720

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007001590A CL2007001590A1 (es) 2006-06-05 2007-06-01 Compuestos derivados de tioxantina; inhibidores de la enzima mieloperoxidasa (mpo); composicion farmaceutica; y su uso para tratar desordenes inflamatorios como esclerosis multiple, mal de parkinson, ateroesclerosis, enfermedad pulmonar obstructiva cronica (copd), bronquitis infecciosa y eosinofilica y fibrosis quistica.

Country Status (20)

Country Link
US (2) US7943625B2 (es)
EP (1) EP2029598A4 (es)
JP (1) JP2009539828A (es)
KR (1) KR20090014189A (es)
CN (1) CN101460498A (es)
AR (1) AR061134A1 (es)
AU (1) AU2007256005B2 (es)
BR (1) BRPI0712310A2 (es)
CA (1) CA2653774A1 (es)
CL (1) CL2007001590A1 (es)
EC (1) ECSP088965A (es)
IL (1) IL195287A0 (es)
MX (1) MX2008014991A (es)
NO (1) NO20085269L (es)
RU (1) RU2435772C2 (es)
TW (1) TW200804383A (es)
UA (1) UA94606C2 (es)
UY (1) UY30387A1 (es)
WO (1) WO2007142576A1 (es)
ZA (1) ZA200809800B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090053176A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Combination 937
US20110144049A1 (en) * 2009-10-21 2011-06-16 Serebruany Victor L Treating Cardiac Arrhythmias, Heart Failure, Peripheral Artery Disease and Stroke with Cyclopentyl-Triazolo-Pyrimidine or Derivative Thereof
WO2012151576A1 (en) * 2011-05-05 2012-11-08 Robert Sackstein Methods of treating complications and disorders associated with g-csf administration
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
US9221821B2 (en) 2012-06-05 2015-12-29 Forest Laboratories Holdings, Limited Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds
WO2015134210A1 (en) 2014-03-03 2015-09-11 Principia Biopharma, Inc. BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
WO2015196245A1 (en) * 2014-06-25 2015-12-30 Adelaide Research & Innovation Pty Ltd Modulation of osteogenesis and or angiogenesis by modulating peroxidase functionality
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
WO2016191172A1 (en) 2015-05-22 2016-12-01 Principia Biopharma Inc. Quinolone derivatives as fibroblast growth factor receptor inhibitors
PE20180521A1 (es) 2015-06-03 2018-03-14 Principia Biopharma Inc Inhibidores de tirosina-cinasas
JP2025528217A (ja) 2022-08-18 2025-08-26 アストラゼネカ・アクチエボラーグ ミエロペルオキシダーゼの阻害剤
CN120265633A (zh) * 2022-12-09 2025-07-04 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135753A (en) * 1961-05-10 1964-06-02 Burroughs Wellcome Co Alkylthiopurines and method
SE7810947L (sv) 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
GB8418430D0 (en) * 1984-07-19 1984-08-22 Beecham Wuelfing Gmbh & Co Kg Treatment
US4710503A (en) 1985-02-07 1987-12-01 Euroceltique S.A. 6-thioxanthine derivatives
WO1989006125A1 (en) 1987-12-31 1989-07-13 Smithkline Beckman Corporation 4-aralkyl-5-substituted-1,2,4-triazole-5-thiols
DK440989A (da) 1988-09-12 1990-03-13 Smithkline Beecham Corp Dopamin-beta-hydroxylase inhibitorer
JPH02160235A (ja) 1988-12-13 1990-06-20 Konica Corp ハロゲン化銀カラー写真画像の形成方法
AU5436790A (en) * 1989-04-19 1990-11-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Sulfer-containing xanthine derivatives as adenosin antagonists
EP0430300A3 (en) 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
US5100906A (en) 1990-04-19 1992-03-31 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
US6046019A (en) * 1991-07-09 2000-04-04 Goumeniouk; Alexander P. Diagnostic kits and methods for making granulocyte cell counts
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
PL314605A1 (en) * 1993-11-26 1996-09-16 Pfizer Isoxazolin compounds as anti-inflammatory agents
US5489598A (en) * 1994-06-08 1996-02-06 Warner-Lambert Company Cytoprotection utilizing aryltriazol-3-thiones
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
CA2206287C (en) * 1994-12-13 2001-03-20 Mark Chasin Aryl thioxanthines
WO1996018400A1 (en) 1994-12-13 1996-06-20 Euro-Celtique, S.A. Trisubstituted thioxanthines
US5756511A (en) * 1995-04-03 1998-05-26 Cell Therapeutics, Inc. Method for treating symptoms of a neurodegenerative condition
US6294541B1 (en) * 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US5976823A (en) * 1997-03-19 1999-11-02 Integrated Biomedical Technology, Inc. Low range total available chlorine test strip
WO1999012546A1 (en) 1997-09-05 1999-03-18 Kyowa Hakko Kogyo Co., Ltd. Remedial agent for neural degeneration
WO1999014204A1 (en) 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6319928B1 (en) * 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
DZ3019A1 (fr) 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
JP2002541078A (ja) 1999-04-02 2002-12-03 ユーロ−セルティーク，エス．エー． ホスホジエステラーゼｉｖ阻害活性を有するプリン誘導体
GB2362101A (en) 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
FR2811989A1 (fr) 2000-07-18 2002-01-25 Sanofi Synthelabo Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique
US6855817B2 (en) 2000-07-21 2005-02-15 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
FR2819723B1 (fr) * 2001-01-23 2006-11-17 Arnaud Mainnemare Composition halogene, son procede de preparation et ses utilisations
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
SE0103766D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab Novel assay
JP4095446B2 (ja) 2001-05-08 2008-06-04 アストラゼネカ・アクチエボラーグ 酵素ミエロペルオキシダーゼの阻害剤を検出するための検定
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
ES2208063B1 (es) 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
RU2223273C1 (ru) * 2002-08-16 2004-02-10 Давлетьярова Альпия Васильевна Производные 1,3-диметил-8-(2-гидроксипропил-1) тиоксантина, проявляющие биологическую активность
SE0301232D0 (sv) 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
SE0302756D0 (sv) 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MXPA06004789A (es) 2003-10-31 2006-07-03 Cv Therapeutics Inc Antagonistas del receptor de adenosina a2b.
BRPI0507604A (pt) 2004-02-14 2007-07-03 Smithkline Beecham Corp medicamentos com atividade de receptor hm74a
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
SE0402591D0 (sv) 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
JP2009539828A (ja) 2009-11-19
MX2008014991A (es) 2008-12-05
EP2029598A1 (en) 2009-03-04
NO20085269L (no) 2009-03-05
ECSP088965A (es) 2009-01-30
RU2435772C2 (ru) 2011-12-10
UY30387A1 (es) 2008-01-31
CA2653774A1 (en) 2007-12-13
US20080221133A1 (en) 2008-09-11
CN101460498A (zh) 2009-06-17
UA94606C2 (ru) 2011-05-25
US7943625B2 (en) 2011-05-17
TW200804383A (en) 2008-01-16
KR20090014189A (ko) 2009-02-06
US20090131459A1 (en) 2009-05-21
WO2007142576A1 (en) 2007-12-13
BRPI0712310A2 (pt) 2012-01-17
RU2008145971A (ru) 2010-07-20
EP2029598A4 (en) 2010-02-17
AU2007256005B2 (en) 2011-03-17
IL195287A0 (en) 2009-08-03
AR061134A1 (es) 2008-08-06
ZA200809800B (en) 2010-04-28
AU2007256005A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
CL2007001590A1 (es) Compuestos derivados de tioxantina; inhibidores de la enzima mieloperoxidasa (mpo); composicion farmaceutica; y su uso para tratar desordenes inflamatorios como esclerosis multiple, mal de parkinson, ateroesclerosis, enfermedad pulmonar obstructiva cronica (copd), bronquitis infecciosa y eosinofilica y fibrosis quistica.
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
CL2007001972A1 (es) Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos.
CL2007003819A1 (es) Compuestos derivados de isoquinolina e isoquinolinona; composicion farmaceutica; y su uso para tratar y/o prevenir hipertension, retinopatia, glaucoma, fibrosis pulmonar, alzheimer, entre otras enfermedades.
CL2007003820A1 (es) Compuestos derivados de isoquinolinona sustituidos con cicloalquilamina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir hipertension, retinopatia, glaucoma, fibrosis pulmonar, alzheimer, sida, entre otra
MX383583B (es) Composiciones organicas para tratar enfermedades relacionadas con beta-enac.
UA117464C2 (uk) Фармацевтична композиція для лікування захворювання, опосередкованого трансмембранним регулятором провідності муковісцидозу cftr
BR112012033197A2 (pt) métodos e composições para liberação de cns de n-sulfatase de heparano.
ATE447568T1 (de) Neue pyrinderivate
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
CL2008000404A1 (es) Sal cristalina de napadisilato de 5-(2-[[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como asma o epoc.
EA200970487A1 (ru) Применение пролекарств аналогов гамк для лечения заболеваний
MX2007016462A (es) Composiciones topicas para tratar la piel.
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
CL2011001977A1 (es) Compuestos derivados de triazolopiridina, inhibidores de proteinas cinasas activadas por mitogeno p38; composicion farmaceutica; y su uso para el tratamiento de neumonia eosinofilica cronica, asma, enfermedad pulmonar obstructiva cronica y sindrome de angustia respiratoria en adultos, entre otras enfermedades.
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
CL2008001818A1 (es) Ácido {4,6-bis(dimetilamino)-2-(4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il}acético amorfo y sus formas cristalinas i y ii; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras.
CL2011000696A1 (es) Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc
DE602006014821D1 (de) Ex-vivo-verfahren zur genzuführung
CL2007003754A1 (es) Compuestos derivados de aril(heteroaril)alquil-amina; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como bronquitis, enfisema pulmonar y epoc.
CL2012001712A1 (es) Compuestos derivados de heterociclos nitrogenados, moduladores de crth2; composición farmacéutica; y su uso para preparar un medicamento útil en el tratamiento de asma, dermatitis alérgica, rinitis alérgica, bronquitis crónica, fibrosis pulmonar idiopática, entre otras.
CL2009000250A1 (es) Compuestos derivados de pirazolo[3,4-b]piridina carboxamida; composicion farmaceutica que los comprende; y su uso en el tratamiento del asma, epoc y rinitis.
CL2008003495A1 (es) Compuestos derivados de pirazol; composicion farmaceutica, metodo de preparacion y; su uso para tratar una enfermedad mediada por 5-lo tal como asma, broncocontriccion, enfisema, enfermedades obstructivas o inflamatorias de las vias respiratorias, bronquitis, lesion pulmonar aguda, bronquiectasia, rinitis alergica, entre otras.
CL2008000973A1 (es) Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.